Over the past decade, much of the research on cancer‐related BCAAs metabolism has focused on branched‐chain amino acid transaminase 1 and 2 (BCAT1/2), which play essential roles in the pathogenesis of various cancer types, including AML,[11] GBM,[18] gastric cancer,[42] and PDAC.[13, 14] These enzymes are considered potential therapeutic targets. This evidence concerns the gene BCAT1 and gastric cancer.